title: "Sequential" boron neutron capture therapy (BNCT): a novel approach to BNCT for the treatment of oral cancer in the hamster cheek pouch model.
abstract: In the present study the therapeutic effect and potential toxicity of the novel "Sequential" boron neutron capture therapy (Seq-BNCT) for the treatment of oral cancer was evaluated in the hamster cheek pouch model at the RA-3 Nuclear Reactor. Two groups of animals were treated with "Sequential" BNCT, i.e., BNCT mediated by boronophenylalanine (BPA) followed by BNCT mediated by sodium decahydrodecaborate (GB-10) either 24 h (Seq-24h-BNCT) or 48 h (Seq-48h-BNCT) later. In an additional group of animals, BPA and GB-10 were administered concomitantly [(BPA + GB-10)-BNCT]. The single-application BNCT was to the same total physical tumor dose as the "Sequential" BNCT treatments. At 28 days post-treatment, Seq-24h-BNCT and Seq-48h-BNCT induced, respectively, overall tumor responses of 95 ± 2% and 91 ± 3%, with no statistically significant differences between protocols. Overall response for the single treatment with (BPA + GB-10)-BNCT was 75 ± 5%, significantly lower than for Seq-BNCT. Both Seq-BNCT protocols and (BPA + GB-10)-BNCT induced reversible mucositis in the dose-limiting precancerous tissue around treated tumors, reaching Grade 3/4 mucositis in 47 ± 12% and 60 ± 22% of the animals, respectively. No normal tissue toxicity was associated with tumor response for any of the protocols. "Sequential" BNCT enhanced tumor response without an increase in mucositis in dose-limiting precancerous tissue.
authors.affiliation: Department of Radiobiology, Constituyentes Atomic Center, National Atomic Energy Commission, Argentina.
authors.forename: Ana J
authors.initials: AJ
authors.lastname: Molinari
authors.forename: Emiliano C C
authors.initials: EC
authors.lastname: Pozzi
authors.forename: Andrea
authors.initials: A
authors.lastname: Monti Hughes
authors.forename: Elisa M
authors.initials: EM
authors.lastname: Heber
authors.forename: Marcela A
authors.initials: MA
authors.lastname: Garabalino
authors.forename: Silvia I
authors.initials: SI
authors.lastname: Thorp
authors.forename: Marcelo
authors.initials: M
authors.lastname: Miller
authors.forename: Maria E
authors.initials: ME
authors.lastname: Itoiz
authors.forename: Romina F
authors.initials: RF
authors.lastname: Aromando
authors.forename: David W
authors.initials: DW
authors.lastname: Nigg
authors.forename: Jorge
authors.initials: J
authors.lastname: Quintana
authors.forename: Gustavo A
authors.initials: GA
authors.lastname: Santa Cruz
authors.forename: Verónica A
authors.initials: VA
authors.lastname: Trivillin
authors.forename: Amanda E
authors.initials: AE
authors.lastname: Schwint
mesh_terms: D000818:Animals; D016754:Boron Neutron Capture Therapy / Q000009:adverse effects* / Q000379:methods*; D002610:Cheek; D006224:Cricetinae; D019583:Dose Fractionation, Radiation; D004307:Dose-Response Relationship, Radiation; D008647:Mesocricetus; D009062:Mouth Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D052016:Mucositis / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control; D011832:Radiation Injuries / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control; D011879:Radiotherapy Dosage; D016896:Treatment Outcome